Ziconotide: Phase III

ELN reported that 57 percent of the 256 patients in its Phase III trial had significant pain relief with intrathecal administration of ziconotide. In the trial, 98 percent of the patients had chronic neuropathic pain for >1 year, and all had failed systemic opioid analgesics including intraspinal morphine. Side effects such as dizziness and nausea resolved upon dose reduction or symptomatic treatment. The data were reported at the American Pain Society meeting in San Diego. ...